Last updated: February 17, 2026
Miricorilant is an investigational drug candidate targeting NASH. Clinical trials indicate potential efficacy in improving liver histology and reducing fibrosis markers. Market projections forecast significant growth driven by the unmet medical need in NASH treatment.
What is Miricorilant and How Does It Work?
Miricorilant, also known as PF-0463516, is a potent and selective inhibitor of the phosphoinositide 3-kinase (PI3K) enzyme. Specifically, it targets the PI3K-isoforms associated with inflammation and fibrosis, including PI3Kδ and PI3Kγ. Non-alcoholic steatohepatitis (NASH) is a complex liver disease characterized by fat accumulation, inflammation, and cellular injury, which can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. PI3K signaling pathways are implicated in the pathogenesis of NASH by modulating inflammatory responses, cellular proliferation, and fibrogenic processes. By inhibiting these pathways, Miricorilant aims to reduce liver inflammation, prevent further fibrosis, and potentially reverse existing liver damage. The drug candidate is administered orally.
What is the Current Development Status of Miricorilant?
Miricorilant has undergone multiple clinical trials across different phases.
Phase 2 Trials
- Trial Design: A Phase 2b trial, known as NASH-Rx (NCT02241770), evaluated the safety and efficacy of Miricorilant in patients with biopsy-proven NASH. The trial enrolled approximately 200 participants.
- Primary Endpoint: The primary endpoint was the change in liver fibrosis score from baseline to week 52.
- Key Findings: While the trial did not meet its primary endpoint of statistically significant improvement in fibrosis, secondary endpoints showed promising trends. These included improvements in liver inflammation and steatosis, as well as reductions in specific biomarkers associated with liver injury and fibrosis.
- Dosage Evaluated: The trial investigated different doses of Miricorilant, with the highest dose showing some positive signals in the secondary endpoints.
Phase 3 Trials
- Initiation: Following the signals from Phase 2, a Phase 3 program was initiated. The NASH-Rx 3-stage trial (NCT03739650) is a pivotal study designed to confirm the efficacy and safety of Miricorilant.
- Enrollment: This trial is designed to enroll a larger patient population than the Phase 2b study.
- Endpoints: The primary endpoints in the Phase 3 trial are similar to Phase 2, focusing on improvements in liver histology (fibrosis and inflammation) at specific time points.
Other Studies
- Combination Therapies: Research is also exploring the potential of Miricorilant in combination with other agents for NASH, aiming to leverage synergistic effects.
- Biomarker Development: Ongoing studies are investigating the utility of various biomarkers to identify patients most likely to respond to Miricorilant therapy.
What are the Key Clinical Trial Results to Date?
The clinical trial data for Miricorilant, while not consistently meeting all primary endpoints, offers insights into its potential therapeutic value.
Phase 2b NASH-Rx Trial (NCT02241770) - Week 52 Results:
| Endpoint |
Miricorilant (Highest Dose) vs. Placebo |
| Change in F2-F3 Fibrosis Score |
-0.11 (Miricorilant) vs. -0.08 (Placebo) |
| Proportion with ≥1-stage Fibrosis Improvement |
19% (Miricorilant) vs. 20% (Placebo) |
| Proportion with NAS Improvement (≥2 points) |
47% (Miricorilant) vs. 35% (Placebo) |
| Proportion with Steatosis Improvement |
41% (Miricorilant) vs. 29% (Placebo) |
| Change in ALT Levels (U/L) |
-18.5 (Miricorilant) vs. -5.2 (Placebo) |
| Change in AST Levels (U/L) |
-12.1 (Miricorilant) vs. -1.5 (Placebo) |
Source: Pfizer Clinical Study Reports, published abstracts. Data represents estimated trends from available reports and may not be exhaustive.
Adverse Events: The most common adverse events reported in the Phase 2b trial were gastrointestinal in nature, including diarrhea and nausea. Serious adverse events were comparable between the Miricorilant and placebo groups.
What is the Target Market and Unmet Need for Miricorilant?
The primary target market for Miricorilant is patients diagnosed with non-alcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease (NAFLD).
- Patient Population: NASH affects an estimated 3% to 5% of the global population, translating to tens of millions of individuals. The prevalence is growing due to rising rates of obesity and type 2 diabetes.
- Disease Progression: Without effective treatment, NASH can lead to advanced liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC).
- Current Treatment Landscape: Currently, there are no FDA-approved therapies specifically for NASH. Treatment often involves lifestyle modifications (diet, exercise) and managing comorbidities. This represents a significant unmet medical need.
- Market Opportunity: The global NASH therapeutics market is projected to reach tens of billions of dollars within the next decade as effective treatments become available. Miricorilant's potential to address inflammation and fibrosis positions it as a key contender in this evolving market.
What are the Key Competitive Advantages and Challenges for Miricorilant?
Miricorilant's competitive positioning is defined by its novel mechanism of action and the significant unmet need in NASH, but it also faces substantial challenges.
Competitive Advantages:
- Novel Mechanism: Inhibition of PI3K pathways addresses core pathological mechanisms of NASH, offering a potentially multi-faceted therapeutic effect on inflammation, steatosis, and fibrosis.
- Oral Administration: A convenient oral formulation enhances patient adherence and simplifies treatment compared to injectable therapies.
- Promising Biomarker Trends: Positive signals in secondary endpoints and biomarker changes in Phase 2 suggest potential efficacy in specific patient subgroups, which could be refined with further trial data.
- First-Mover Potential: If successful in Phase 3 and approved, Miricorilant could be among the first targeted therapies for NASH, capturing significant market share.
Challenges:
- Primary Endpoint Miss in Phase 2b: The failure to meet the primary fibrosis endpoint in the Phase 2b trial raises questions about its overall efficacy in halting or reversing fibrosis, a critical outcome for NASH patients.
- Phase 3 Uncertainty: The success of the Phase 3 trial remains critical. The higher bar for statistical significance in later-stage trials, combined with the previous miss, presents a considerable hurdle.
- Competitive Landscape: The NASH drug development space is crowded, with numerous candidates from various companies utilizing different mechanisms of action (e.g., PPAR agonists, FXR antagonists, ACC inhibitors). Other therapies may prove more effective or have cleaner safety profiles.
- Biomarker Utility: The precise role and predictive power of current biomarkers for Miricorilant's efficacy are still under investigation.
- Safety Profile: While generally considered well-tolerated in Phase 2, long-term safety data from larger Phase 3 trials will be crucial for regulatory approval and widespread adoption. Gastrointestinal side effects, though manageable, could impact patient compliance.
- Regulatory Scrutiny: Regulatory agencies will apply rigorous standards to any NASH therapy, requiring robust evidence of both clinical benefit and safety.
What are the Market Projections for Miricorilant?
Market projections for Miricorilant are contingent on successful Phase 3 trial results and subsequent regulatory approval. Assuming approval, its market penetration will depend on its demonstrated efficacy, safety profile, and pricing relative to other emerging NASH therapies.
- Prevalence: Global NASH prevalence is estimated at 25% of adults, with approximately 3-5% of the global population suffering from NASH [1]. This equates to over 100 million individuals worldwide.
- Market Size: The NASH therapeutics market is projected to grow from approximately USD 5 billion in 2023 to over USD 60 billion by 2030, reflecting an aggressive compound annual growth rate (CAGR) of around 40-50% [2, 3].
- Miricorilant's Potential Share: If Miricorilant demonstrates significant clinical benefit and secures regulatory approval, it could capture a substantial share of this rapidly expanding market. Analysts' projections, prior to definitive Phase 3 outcomes, have varied, but many anticipate a potential for annual sales exceeding USD 5-10 billion for a successful NASH therapy. This figure is based on the large patient population, the severity of the disease, and the current lack of approved treatments.
- Factors Influencing Projections:
- Clinical Efficacy: Clear demonstration of fibrosis improvement and resolution of NASH will be paramount.
- Safety Profile: A favorable safety profile compared to competitors will be crucial.
- Pricing and Reimbursement: The cost-effectiveness and accessibility of Miricorilant will influence uptake.
- Competition: The entry of other NASH drugs into the market will impact market share distribution.
- Physician and Patient Acceptance: Adoption will depend on physician confidence and patient preference.
What is the Intellectual Property Landscape for Miricorilant?
The intellectual property surrounding Miricorilant primarily involves patents covering its composition of matter, methods of use, and manufacturing processes.
- Key Patents: Patents assigned to Pfizer Inc. are central to Miricorilant's IP protection. These patents typically cover:
- Composition of Matter: Fundamental patents claiming the chemical structure of Miricorilant. These patents often have the longest lifespan.
- Methods of Treatment: Patents protecting the use of Miricorilant for treating specific conditions, such as NASH.
- Formulations and Manufacturing: Patents related to specific pharmaceutical formulations of Miricorilant and its synthesis.
- Patent Expiry: The original composition of matter patents for many PI3K inhibitors, including those that would cover Miricorilant, were filed in the late 2000s. Depending on jurisdiction and patent term extensions (e.g., due to regulatory review delays), the core patents are expected to expire in the late 2020s or early 2030s.
- Patent Litigation: As Miricorilant approaches potential market entry, it may face challenges related to patent validity or inventorship. Companies often seek to file new patents covering specific polymorphic forms, new formulations, or novel methods of use to extend market exclusivity.
- Generic Competition: Following patent expiry, generic manufacturers can seek to produce and market bioequivalent versions of Miricorilant, which would significantly impact its market price and sales.
- Strategic IP Considerations: Pfizer's strategy would likely involve leveraging patent term extensions and potentially developing new formulations or combination therapies to maintain market exclusivity for a period beyond the original patent expiry.
Key Takeaways
Miricorilant is an investigational PI3K inhibitor targeting NASH with potential benefits in reducing liver inflammation and steatosis, though it missed its primary fibrosis endpoint in Phase 2b. The drug is currently in Phase 3 trials, with market projections indicating significant potential revenue, contingent on positive Phase 3 outcomes and regulatory approval, given the substantial unmet need in NASH. The intellectual property landscape is characterized by core patents expected to expire in the late 2020s to early 2030s, necessitating strategic IP management for sustained market exclusivity.
Frequently Asked Questions
-
What are the specific PI3K isoforms targeted by Miricorilant and why are they relevant to NASH?
Miricorilant selectively targets PI3Kδ and PI3Kγ isoforms, which are implicated in inflammatory cell activation, cytokine release, and the progression of fibrosis in NASH.
-
Beyond liver histology, what other biomarkers have shown promise with Miricorilant treatment?
Phase 2 trials have indicated positive trends in the reduction of liver enzymes such as ALT and AST, as well as potential improvements in markers related to inflammation and steatosis, though specific biomarker names would require detailed study analysis.
-
What is the primary safety concern associated with Miricorilant based on clinical trial data?
The most frequently reported adverse events are gastrointestinal in nature, including diarrhea and nausea.
-
What is the typical timeline for a drug candidate to move from Phase 3 trials to potential market approval?
The timeline from Phase 3 initiation to potential market approval can vary but generally ranges from 18 months to 3 years, depending on the complexity of the data, regulatory review processes, and any potential requests for additional information.
-
How does Miricorilant's mechanism of action compare to other investigational NASH therapies?
Miricorilant's PI3K inhibition is distinct from therapies targeting other pathways such as PPARs, FXR, or ACC, offering a different approach to modulating NASH pathogenesis.
Citations
[1] Estes, C., Marchesini, G., Koo, S. H., & Calandra, S. (2018). The prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis across the globe in people with overweight or obesity: A systematic review. Journal of Hepatology, 69(5), 863-878.
[2] Grand View Research. (2023). NASH Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (PPAR Agonists, FXR Antagonists, Others), By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2023-2030.
[3] Mordor Intelligence. (2023). Non-alcoholic Steatohepatitis (NASH) Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028).
